Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1963 1
1977 1
1987 2
1988 1
1989 5
1990 2
1991 2
1992 1
1993 2
1994 3
1996 2
1997 2
1998 2
1999 3
2000 4
2001 3
2002 3
2003 6
2004 2
2005 3
2006 7
2007 8
2008 5
2009 11
2010 11
2011 6
2012 10
2013 17
2014 29
2015 29
2016 46
2017 47
2018 60
2019 71
2020 92
2021 97
2022 98
2023 91
2024 37

Text availability

Article attribute

Article type

Publication date

Search Results

727 results

Results by year

Filters applied: . Clear all
The following term was not found in PubMed: Koshesh
Page 1
Did you mean M. koushesh saba (5 results)?
Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes.
Reddel HK, Bacharier LB, Bateman ED, Brightling CE, Brusselle GG, Buhl R, Cruz AA, Duijts L, Drazen JM, FitzGerald JM, Fleming LJ, Inoue H, Ko FW, Krishnan JA, Levy ML, Lin J, Mortimer K, Pitrez PM, Sheikh A, Yorgancioglu AA, Boulet LP. Reddel HK, et al. Eur Respir J. 2021 Dec 31;59(1):2102730. doi: 10.1183/13993003.02730-2021. Print 2022 Jan. Eur Respir J. 2021. PMID: 34667060 Free PMC article. Review.
GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because of the risks of SABA-only treatment and SABA overuse, and evidence for benefit of inhaled corticosteroids (ICS). Large trials …
GINA recommends that asthma in adults and adolescents should not be treated solely with short-acting beta(2)-agonist (SABA), because …
Albuterol-Budesonide Fixed-Dose Combination Rescue Inhaler for Asthma.
Papi A, Chipps BE, Beasley R, Panettieri RA Jr, Israel E, Cooper M, Dunsire L, Jeynes-Ellis A, Johnsson E, Rees R, Cappelletti C, Albers FC. Papi A, et al. N Engl J Med. 2022 Jun 2;386(22):2071-2083. doi: 10.1056/NEJMoa2203163. Epub 2022 May 15. N Engl J Med. 2022. PMID: 35569035 Clinical Trial.
BACKGROUND: As asthma symptoms worsen, patients typically rely on short-acting beta(2)-agonist (SABA) rescue therapy, but SABAs do not address worsening inflammation, which leaves patients at risk for severe asthma exacerbations. ...
BACKGROUND: As asthma symptoms worsen, patients typically rely on short-acting beta(2)-agonist (SABA) rescue therapy, but SABAs do no …
Controlled Trial of Budesonide-Formoterol as Needed for Mild Asthma.
Beasley R, Holliday M, Reddel HK, Braithwaite I, Ebmeier S, Hancox RJ, Harrison T, Houghton C, Oldfield K, Papi A, Pavord ID, Williams M, Weatherall M; Novel START Study Team. Beasley R, et al. N Engl J Med. 2019 May 23;380(21):2020-2030. doi: 10.1056/NEJMoa1901963. Epub 2019 May 19. N Engl J Med. 2019. PMID: 31112386 Clinical Trial.
BACKGROUND: In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe exacerbation of asthma than as-needed use of a short-acting beta(2)-agonist (SABA); the risk was similar to that of budesonide mainte …
BACKGROUND: In double-blind, placebo-controlled trials, budesonide-formoterol used on an as-needed basis resulted in a lower risk of severe …
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck.
Ferris RL, Blumenschein G Jr, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, Worden F, Saba NF, Iglesias Docampo LC, Haddad R, Rordorf T, Kiyota N, Tahara M, Monga M, Lynch M, Geese WJ, Kopit J, Shaw JW, Gillison ML. Ferris RL, et al. N Engl J Med. 2016 Nov 10;375(19):1856-1867. doi: 10.1056/NEJMoa1602252. Epub 2016 Oct 8. N Engl J Med. 2016. PMID: 27718784 Free PMC article. Clinical Trial.
Overuse of short-acting β2-agonists in asthma is associated with increased risk of exacerbation and mortality: a nationwide cohort study of the global SABINA programme.
Nwaru BI, Ekström M, Hasvold P, Wiklund F, Telg G, Janson C. Nwaru BI, et al. Eur Respir J. 2020 Apr 16;55(4):1901872. doi: 10.1183/13993003.01872-2019. Print 2020 Apr. Eur Respir J. 2020. PMID: 31949111 Free PMC article.
SABA use was grouped into 3-5, 6-10 and 11 canisters per baseline-year. ...CONCLUSION: One-third of asthma patients in Sweden collected three or more SABA canisters annually. SABA overuse was associated with increased risks of exacerbation and mortality. ...
SABA use was grouped into 3-5, 6-10 and 11 canisters per baseline-year. ...CONCLUSION: One-third of asthma patients in Sweden collect …
The management of mild asthma.
O'Byrne PM, Reddel HK, Beasley R. O'Byrne PM, et al. Eur Respir J. 2021 Apr 8;57(4):2003051. doi: 10.1183/13993003.03051-2020. Print 2021 Apr. Eur Respir J. 2021. PMID: 33093120 Free article. Review.
The purpose of this review is to evaluate the efficacy of reliever medications that contain ICS compared with SABA as reliever, or with maintenance ICS and SABA as reliever, in mild asthma patients.Nine studies were identified that have evaluated the use of ICS as a …
The purpose of this review is to evaluate the efficacy of reliever medications that contain ICS compared with SABA as reliever, or wi …
Nivolumab Plus Ipilimumab Versus EXTREME Regimen as First-Line Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck: The Final Results of CheckMate 651.
Haddad RI, Harrington K, Tahara M, Ferris RL, Gillison M, Fayette J, Daste A, Koralewski P, Zurawski B, Taberna M, Saba NF, Mak M, Kawecki A, Girotto G, Alvarez Avitia MA, Even C, Toledo JGR, Guminski A, Müller-Richter U, Kiyota N, Roberts M, Khan TA, Miller-Moslin K, Wei L, Argiris A. Haddad RI, et al. J Clin Oncol. 2023 Apr 20;41(12):2166-2180. doi: 10.1200/JCO.22.00332. Epub 2022 Dec 6. J Clin Oncol. 2023. PMID: 36473143 Free PMC article. Clinical Trial.
PURPOSE: CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab plus cisplatin/carboplatin plus fluorouracil six cycles, then cetuximab maintenance) in recurrent/metastatic squamous cell carcinoma of the …
PURPOSE: CheckMate 651 (ClinicalTrials.gov identifier: NCT02741570) evaluated first-line nivolumab plus ipilimumab versus EXTREME (cetuximab …
Expert Consensus on SABA Use for Asthma Clinical Decision-Making: A Delphi Approach.
Lugogo N, O'Connor M, George M, Merchant R, Bensch G, Portnoy J, Oppenheimer J, Castro M. Lugogo N, et al. Curr Allergy Asthma Rep. 2023 Nov;23(11):621-634. doi: 10.1007/s11882-023-01111-z. Epub 2023 Nov 22. Curr Allergy Asthma Rep. 2023. PMID: 37991672 Free PMC article. Review.
RECENT FINDINGS: In Phase 1 (n = 100 clinicians), 12% routinely provided patients with 4 SABA prescriptions/year, 73% solicited SABA use frequency at every patient visit, and 21% did not consult asthma guidelines/expert reports. Phase 3 experts (n = 8) reached conse …
RECENT FINDINGS: In Phase 1 (n = 100 clinicians), 12% routinely provided patients with 4 SABA prescriptions/year, 73% solicited SA …
Update on olfactory neuroblastoma.
Lopez F, Agaimy A, Franchi A, Suárez C, Vander Poorten V, Mäkitie AA, Homma A, Eisbruch A, Olsen KD, Saba NF, Nuyts S, Snyderman C, Beitler JJ, Corry J, Hanna E, Hellquist H, Rinaldo A, Ferlito A. Lopez F, et al. Virchows Arch. 2024 Apr;484(4):567-585. doi: 10.1007/s00428-024-03758-z. Epub 2024 Feb 22. Virchows Arch. 2024. PMID: 38386106 Review.
727 results